Floatz Rating
C39/100
Confidence
Indicative
Sponsor
University of Pennsylvania
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03054298CT.gov CAR T Cells in Mesothelin Expressing Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hucart-Meso Cells (this asset) | University of Pennsylvania | P1 | C · 39 |
| Carboplatin | CanariaBio Inc. | P3 | BB |
| Stapuldencel | SOTIO a.s. | P3 | B |
| Interferon Gamma-1B | InterMune | P3 | B |
| Oxaliplatin | University of Utah | P2 | B |
| Gefitinib | Massachusetts General Hospital | P2 | B |
| Anastrozole | Massachusetts General Hospital | P2 | B |
| Oregovamab | CanariaBio Inc. | P3 | B |
| Omburtamab | Memorial Sloan Kettering Cancer Center | P2 | CCC |
+10 more in the Peritoneal Carcinoma cohort
Other indications for Hucart-Meso Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peritoneal Mesothelioma | — | P1 | C · 39 |
| Pleural Mesothelioma | — | P1 | C · 39 |
| Lung Adenocarcinoma | — | P1 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hucart-Meso Cells in Peritoneal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hucart-meso-cells-peritoneal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →